Compare EPAM Systems Inc (EPAM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Summit Therapeutics Inc — how do they compare? EPAM Systems Inc trades at $112.92 (market cap $5.87B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.3× EPAM Systems Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Summit Therapeutics Inc for 16 Days on average.
| EPAM | SMMT | |
|---|---|---|
Market Cap | $5.87B | $13.71B |
Volume | 847,420 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $221.40 | $26.38 |
52-Week Low | $76.04 | $12.43 |
Typical Hold Time | 37 Days | 16 Days |
Enterprise Value | $5.24B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.24, up 4.54% today, reflecting strong momentum. The stock shows a bullish technical trend, trading near resistance at $115. Fundamentally, EPAM reported Q2 2026 EPS of $3.38, beating estimates, with revenue reaching $5.46B in 2025. Recent news highlights a partnership with Wiz for cloud security and activist investor Engine Capital urging share buybacks, signaling confidence in undervaluation.
The outlook is positive, supported by a consensus price target of $119 and strong analyst buy ratings (59.46%). However, risks include slower North American growth and AI disruption to legacy services. The stock presents a value opportunity with a P/E of 15.45, but investors should monitor execution on AI-native revenue growth and margin sustainability.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
